Related Experiment Video

Updated: Jul 15, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Severe human metapneumovirus infection in hospitalized children

Benjamin Estrada1, Macharia Carter, Sailen Barik

  • 1Division of Pediatric Infectious Diseases, University of South Alabama, Mobile, Alabama 36604, SUA. bestrada@ usouthal.edu

Clinical Pediatrics
|April 10, 2007
PubMed

Insights

Human metapneumovirus (hMPV) causes significant respiratory illness in children, often requiring hospitalization and oxygen. Some children experienced severe disease or life-threatening events, with prolonged illness in those with asthma or neuromuscular conditions.

Area of Science:

  • Pediatric infectious diseases
  • Virology
  • Respiratory medicine

Background:

  • Human metapneumovirus (hMPV) is an emerging respiratory pathogen.
  • hMPV infection can cause significant upper and lower respiratory tract disease in children.

Purpose of the Study:

  • To describe the clinical course of hospitalized children with human metapneumovirus infection.
  • To identify risk factors and outcomes associated with severe hMPV disease in pediatric patients.

Main Methods:

  • Retrospective analysis of 11 hospitalized children diagnosed with hMPV.
  • Diagnosis confirmed via reverse transcription-polymerase chain reaction (RT-PCR).

Main Results:

  • 82% of patients required oxygen supplementation.
  • 45% developed severe disease, with some needing mechanical ventilation.
  • 27% were hospitalized due to apparent life-threatening events.
  • Children with asthma or neuromuscular disease experienced prolonged hospital stays.

Conclusions:

  • Human metapneumovirus infection can lead to severe respiratory illness in hospitalized children.
  • Underlying conditions like asthma and neuromuscular disease are associated with prolonged illness.
  • Prompt diagnosis and supportive care are crucial for managing hMPV infections in pediatric populations.

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: